

UPADACITINIB prolonged-release tablets (RINVOQ® ▼) for treating ulcerative colitis

The Pan Mersey Area Prescribing Committee does not currently recommend the prescribing of UPADACITINIB prolonged-release tablets (RINVOQ® ▼) for treating ulcerative colitis.

GREY

Upadacitinib is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.^[1]

This recommendation will be reviewed when the [NICE TA](#) is published.

In the meantime, treatment of ulcerative colitis in adults should continue to follow national guidance, local pathways and local formulary choices:

- > NICE guideline [NG130]: [Ulcerative colitis: management](#) (03 May 2019)
- > Pan Mersey APC Formulary [Chapter 1: Gastrointestinal system](#)
- > Pan Mersey APC [Inflammatory Bowel Disease High Cost Drugs Treatment Pathway for Adults](#) (27 July 2022)

References

1. AbbVie Ltd. Summary of Product Characteristics; [RINVOQ 15 mg prolonged-release tablets \(Great Britain\)](#), 23 August 2022. Accessed online 22 September 2022.

Note: Patients who are not eligible for treatment under this statement may be considered on an individual basis where their GP or consultant believes exceptional circumstances exist that warrant deviation from the rule of this policy. In this situation, follow locally defined processes.